November 2015 Issue of The Ophthalmologist

In eye care, anyone with an idea can make a difference

Vasotide, a small molecule that stops VEGF binding to endothelial receptor molecules, has shown promise in animal models and can be delivered using eyedrops

Using a mouse model to shed new light on a genetic cause of enlarged eyeballs

IOL power calculation formulae all have their own strengths and weaknesses – so researchers decided to combine those strengths into a single “super formula”

Vaccination complications as an explanation for retinal hemorrhage in children should not be accepted clinically or legally, new study data suggests

Dichoptic films could offer a new and engaging treatment method for children with amblyopia

A recent study on risk factors for myopia show it doesn’t always pay to be the eldest child…

Swiss researchers have developed methods for performing corneal crosslinking with riboflavin and corneal biomechanical testing in mice – opening up the world of transgenics and molecular testing.

The key to education and development is collaboration. Nowhere is this more obvious than in healthcare

Eleven days, six ophthalmologists, and one small eye hospital in rural Uganda

A team of UK-based eye health professionals bring teaching and equipment to the Mulago National Referral Hospital

Mark chats with Farhad Hafezi on all things excimer laser

Part two of our conversation with A. John Kanellopoulos

Combining sutureless lamellar keratoplasty, phacoemulsification, and IOL implantation in one surgery allows rapid visual rehabilitation in patients with cataract and corneal opacity

Bean-shaped rings can compensate for compromised capsular integrity in bag-in-the-lens IOL implantation

Trypan blue is usually the dye of choice for anterior segment surgeons – but how did it become the king of vital dyes?

Optogenetics holds the potential of reversing blindness in retinal disease – but how far has the field come, and who are the key players?

A patient has undergone a premium refractive cataract procedure, and they’re unhappy. How are you going to fix it?

Sitting Down With... Zoltán Nagy, Head of the Department of Clinical Ophthalmology and the Institute of Health Diagnostics, Dean of the Faculty of Health Sciences, and Director of the Department of Ophthalmology at Semmelweis University, Budapest, Hungary

Preservatives in topical glaucoma therapy: they risk ocular surface disease and future filtration surgery failure, and do nothing to improve efficacy. Is it time to leave them behind?